Clinical Trial 24357
- Cancer Type: Multiple
- Study Type: Treatment
- NCT#: NCT06835569
- Phase: Phase I
- Principal Investigator: Garrido-Laguna, Ignacio
- 813-745-6100
- Or 1-800-679-0775
-
Overview
Study Title:
A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations
-
Treatments
Therapies:
Chemotherapy; Microtubule stabilizing agent; PD-1 monoclonal antibody; Targeted therapy EGFR monoclonal antibody; Topoisomerase I inhibitor; selective KRAS active-state inhibitor
Medications:
ALTA3263 (); Albumin-Bound Paclitaxel (); Alimta (Pemetrexed); CPT-11 (irinotecan); Camptosar (irinotecan); Cetuximab (); Erbitux (Cetuximab); Fluorouracil (); Gemzar (gemcitabine); Oxaliplatin (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin (); eloxatin (Oxaliplatin); gemcitabine (); irinotecan (); leucovorin ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.